Effects of RDEA119 plus rapamycin combination on tumour growth. Effects of RDEA119 plus rapamycin combination on tumour growth in 3 orthotopic primary pancreatic cancer xenografts. A. Body weight during the chronic administration of vehicle control, single agents, and concurrent combination. Due to the different growth rates of these 3 models, the drug administration was initiated on Day 52, 24, and 12 after implantation in OCIP19, 21, and 23, respectively. RDEA119 was administrated at 6.25 mg/kg p.o. b.i.d. (5-day on, 2-day off) and rapamycin at 2 mg/kg i.p. once weekly for 2-4 weeks; all the treatments were well tolerated. Error bars are SEM. B. Tumour weights at the completion of chronic dose administration. Horizontal lines indicate the mean value for each group.